CMS Open Payments · Program Year 2024
HemoSonics LLC
HemoSonics LLC reported $336,614.05 across General Payments, Research, and Ownership to 219 physicians and teaching hospitals across 237 transactions.
- $336.6K Above-median payer
- All-tracks total
- 237 Above-median volume
- Transactions
- 219 Above-median reach
- Recipients
- +$79.7K
- General Payments vs PY2023
HemoSonics LLC reported $336,614.05 across all CMS Open Payments tracks (General + Research + Ownership) to 219 physicians and teaching hospitals in Program Year 2024 - ranking #867 of 1,925 reporting manufacturers (0.0% of the all-tracks industry total); General Payments alone were $100,734.09, averaging $1.5K per recipient.
How HemoSonics LLC's $336.6K all-tracks total breaks down
HemoSonics LLC's payment reach score
Each tracked dimension is percentile-scored against the national companies corpus, then averaged across only the dimensions that apply to this company, a neutral scale measure of reporting activity, not a rating of quality, safety, or ethics.
Overall reach score
F
22/100
Total payments
F
13/100
Transaction volume
F
12/100
Physician reach
F
12/100
Payment type diversity
D
50/100
Data currency: Figures are rendered from the processed CMS Open Payments release. See our methodology for source dates and refresh cadence. Spot a figure that looks wrong? Report a correction.
CMS Sunshine Act warrant
Manufacturer hemosonics-llc HemoSonics LLC
$336.6K · #867/1,925 · 0.0% industry · PY2024
- TOT $336.6K
- RANK #867
- SHARE 0.0%
- TXN 237
- RCP 219
- CAT 4
- GEN $100.7K
- ΔGEN +$79.7K
- TOP1 22.3%
- PY 2024
Volume peers
Nearest volume peer: Noven Pharmaceuticals, Inc. ($337.1K)
HemoSonics LLC sits among 1,925 manufacturers disclosing under the Physician Payments Sunshine Act. Volume peers below are nearest by all-tracks total, not corporate affiliates. Open the company rankings →
Release-over-release change
General Payments changed from PY2023 to PY2024
HemoSonics LLC's CMS-reported General Payments increased by $79.7K (+379.4%) from PY2023 to PY2024.
How this year-over-year comparison is scoped
The comparison uses consecutive CMS program years only (current = prior + 1) from the manufacturer General Payments summary and excludes research and ownership or investment records. Non-consecutive year pairs are not shown as year-over-year change. This General Payments figure is not the all-tracks company total in the hero.
CMS source labels for this exact identifier: PY2022: HEMOSONICS LLCPY2023: HEMOSONICS LLCPY2024: HemoSonics LLC. Matching identifiers support a bounded record comparison; a label difference would be reported as unresolved rather than treated as a corporate event.
Subscribe to this company's source-bounded update feed It publishes only identifier-matched CMS release comparisons, never inferred company events.
General Payments: PY2023 vs PY2024
Annual CMS-reported totals for this company, not an all-category Open Payments total
- PY2023
- $21,013.15
- PY2024
- $100,734.09
What the Data Shows for HemoSonics LLC
CMS Open Payments is not a single ledger: the all-tracks total shown above is General Payments plus Research Payments plus Ownership/Investment interests, each with its own disclosure rules. For HemoSonics LLC, that total blends General Payments (day-to-day consulting, meals, travel and speaking fees, shown separately above) with Research and Ownership/Investment interest records, each governed by its own CMS reporting rules. Data for a given Program Year arrives roughly a year after the period it covers; our methodology page documents the release cadence and how we standardize the tracks for cross-company comparison.
The 4-category breakdown below covers general payments only (see our methodology for how research and ownership payments are reported separately). The largest general-payment category is "Compensation for Services Other Than Consulting" at $37.1K, accounting for 36.8% of this company's General Payments and 7 transactions.
General Payment Breakdown by Type
HemoSonics LLC made 4 types of general payments. "Compensation for Services Other Than Consulting" is the largest category at $37.1K, 36.8% of General Payments.
HemoSonics LLC reports 4 general-payment categories - the top three are Compensation for Services Other Than Consulting (36.8%), Travel and Lodging (29.8%), and Consulting Fee (17.9%). The remaining 1 category make up 15.5% of this company's reported general-payment total. That multi-category mix is the kind of profile single-category reporters cannot show.
How HemoSonics LLC divides its payments
Ranked by total dollars reported per category
| Payment Type | Amount | Transactions | % of Total |
|---|---|---|---|
| Compensation for Services Other Than Consulting | $37.1K | 7 | 36.8% |
| Travel and Lodging | $30.1K | 10 | 29.8% |
| Consulting Fee | $18.0K | 6 | 17.9% |
| Food and Beverage | $15.6K | 196 | 15.5% |
Recipient Concentration in General Payments
The five largest recipient relationships account for $68,351.30 (67.9%) of $100,734.09 in this company's General Payments records across 163 recipients.
General Payments scope note
Program Year 2024 General Payments view only: excludes research and ownership/investment records, so it is not the all-category company total above.
Largest General-Payment relationships for HemoSonics LLC
The five named recipients with the highest reported General Payments from this company
- 1
Melissa Anne Burger
$22,464.88 across 4 reported transactions
- 2
Jonathan Chow
$15,281.74 across 5 reported transactions
- 3
Asad Shah
$13,732.33 across 6 reported transactions
- 4
Joseph Griggs
$12,374.87 across 7 reported transactions
- 5
Dallas Hack
$4,497.48 across 3 reported transactions
Compare this company's payment profile with similarly sized manufacturers in the company comparison tool, and consult the methodology for the CMS source scope.
Spend vs. Concentration
HemoSonics LLC's spend rank (#867 of 1,925, top 45% by spend) and concentration rank (#967 of 1,838, bottom 47% least concentrated) land at roughly the same percentile, an unusually proportionate case where payment size and payment concentration move together.
View all 12 companies in this HHI neighborhood as a list
- Reprise Biomedical, Inc. : $117.0K total payments, HHI 1168
- DentalEZ Alabama, Inc. : $5.9K total payments, HHI 1168
- Hollister Incorporated : $45.3K total payments, HHI 1167
- Kamada Ltd. : $83.4K total payments, HHI 1166
- Pulpdent Corporation : $80.0K total payments, HHI 1162
- Optos, Inc. : $585.3K total payments, HHI 1153
- HemoSonics LLC (this company) : $100.7K total payments, HHI 1152
- Intercept Pharmaceuticals, Inc. : $2.8M total payments, HHI 1149
- Asensus Surgical, Inc. : $207.1K total payments, HHI 1147
- Alcresta Therapeutics, Inc. : $170.2K total payments, HHI 1141
- Pathway Medical Partners, LLC : $66.0K total payments, HHI 1140
- Visionix USA, Inc : $108.9K total payments, HHI 1138
Similarly Concentrated Companies
Companies whose General Payments are spread across recipients about as (un)evenly as HemoSonics LLC's, measured by the same HHI concentration index above, not by payment size.
What HHI 2,500 means here
2,500 is the DOJ/FTC merger-guidelines threshold for "highly concentrated" markets; used here only as a familiar concentration reference, not a legal finding about HemoSonics LLC.
Companies with Similar Payment Volumes
Open a profile or compare a similar company's CMS-reported payment pattern with HemoSonics LLC.
Showing 6 of 1,924 companies with CMS-reported payment data.
Intuitive Surgical Operations, Inc.
UCB Biosciences Inc.
ALK-Abello, Inc
Phadia US Inc.
Carl Zeiss Meditec AG
Put this to use
HemoSonics LLC ranks #867 of 1,925 by all-tracks total payments, led by "Compensation for Services Other Than Consulting".
- See how manufacturer spending compares across the full leaderboard. Top 100 by total payments
- Compare "Compensation for Services Other Than Consulting" spend across every manufacturer, not just HemoSonics LLC. Payment type breakdowns
- New to Open Payments? Learn what these figures do and do not show. Read the guide
Reported payments reflect what companies disclosed to CMS; a payment is not evidence of wrongdoing.
Disclaimer
This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from the CMS Open Payments program. Consult a qualified professional before making decisions based on this data.
Read our methodology - how this data is sourced, computed, and verified.
Every figure on PlainPharmaWatch is rendered directly from federal source data, no number is typed in by an editor. This page draws directly on federal source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of 2026-07-26.